Prioritizing veterinary pharmaceuticals for aquatic environment in Korea
Younghee Kim1, Jinyong Jung, Myunghyun Kim
1School of Public Health, Seoul National University, Seoul 110-799, Republic of Korea.
Environmental Toxicology and Pharmacology
|July 26, 2011
Summary
This study prioritized veterinary pharmaceuticals in Korea based on environmental risk. Eight antibiotics, including amoxicillin and oxytetracycline, require immediate attention to protect aquatic ecosystems.
Area of Science:
- Environmental Science
- Ecotoxicology
- Aquatic Chemistry
Background:
- Pharmaceutical residues pose risks to aquatic ecosystems.
- Prioritization of pharmaceuticals is crucial for risk management.
- Veterinary pharmaceuticals are a significant source of aquatic contamination.
Purpose of the Study:
- To prioritize veterinary pharmaceuticals in Korea based on environmental risk.
- To identify high-risk veterinary drugs for aquatic ecosystems.
- To inform environmental risk management strategies for pharmaceutical contaminants.
Main Methods:
- Prioritization based on usage, environmental entry potential, and toxicological hazard.
- Screening of veterinary pharmaceuticals by sales tonnage.
- Identification of compounds requiring immediate attention.
Main Results:
- Twenty veterinary pharmaceutical compounds were identified as top priority.
- Antibiotics constituted the majority of high-priority compounds.
- Eight specific antibiotics (amoxicillin, enramycin, fenbendazole, florfenicol, ivermectin, oxytetracycline, tylosin, virginiamycin) require immediate focus.
Conclusions:
- This study provides the first prioritization of veterinary pharmaceuticals in Korea.
- Identified high-risk compounds necessitate targeted environmental risk management.
- The findings support the development of strategies to mitigate pharmaceutical pollution in aquatic systems.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...